These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
221 related items for PubMed ID: 8294316
1. Current management of hemophilia B. Roberts HR, Eberst ME. Hematol Oncol Clin North Am; 1993 Dec; 7(6):1269-80. PubMed ID: 8294316 [Abstract] [Full Text] [Related]
2. [Clinical use of factor IX concentrates]. Nyman D. Schweiz Med Wochenschr; 1975 Sep 13; 105(37):1188-90. PubMed ID: 1215901 [Abstract] [Full Text] [Related]
3. Factor IX thrombogenicity: in vivo effects on coagulation activation and a case report of disseminated intravascular coagulation. Small M, Lowe GD, Douglas JT, Forbes CD, Prentice CR. Thromb Haemost; 1982 Aug 24; 48(1):76-7. PubMed ID: 7135346 [Abstract] [Full Text] [Related]
4. Thrombogenicity associated with factor IX complex concentrates. Lusher JM. Semin Hematol; 1991 Jul 24; 28(3 Suppl 6):3-5. PubMed ID: 1780767 [No Abstract] [Full Text] [Related]
5. Myocardial infarction during factor IX infusion in hemophilia B: case report and review of the literature. Najaf SM, Malik A, Quraishi AU, Kazmi K, Kakepoto GN. Ann Hematol; 2004 Sep 24; 83(9):604-7. PubMed ID: 15205916 [Abstract] [Full Text] [Related]
6. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs. Négrier C, Menart C, Attali O, Petit PY, Lienhart A, Dechavanne M, Ingerslev J. Blood Coagul Fibrinolysis; 1998 Mar 24; 9 Suppl 1():S135-41. PubMed ID: 9819045 [Abstract] [Full Text] [Related]
7. In vitro characterization of high purity factor IX concentrates for the treatment of hemophilia B. Limentani SA, Gowell KP, Deitcher SR. Thromb Haemost; 1995 Apr 24; 73(4):584-91. PubMed ID: 7495063 [Abstract] [Full Text] [Related]
8. Clinical evaluation of recombinant factor IX. White G, Shapiro A, Ragni M, Garzone P, Goodfellow J, Tubridy K, Courter S. Semin Hematol; 1998 Apr 24; 35(2 Suppl 2):33-8. PubMed ID: 9565165 [Abstract] [Full Text] [Related]
9. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia. McMillan CW, Greene WB, Blatt PM, White GC, Roberts HR. Instr Course Lect; 1983 Apr 24; 32():210-6. PubMed ID: 6443730 [Abstract] [Full Text] [Related]
12. Disseminated intravascular coagulation after factor IX complex resolved using purified factor IX concentrate. Hadley T, Djulbegovic B. Ann Intern Med; 1991 Oct 15; 115(8):621-2. PubMed ID: 1892334 [No Abstract] [Full Text] [Related]
18. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Kim HC, McMillan CW, White GC, Bergman GE, Horton MW, Saidi P. Blood; 1992 Feb 01; 79(3):568-75. PubMed ID: 1531035 [Abstract] [Full Text] [Related]
19. Haemophilia B: current pharmacotherapy and future directions. Franchini M, Frattini F, Crestani S, Bonfanti C. Expert Opin Pharmacother; 2012 Oct 01; 13(14):2053-63. PubMed ID: 22946758 [Abstract] [Full Text] [Related]
20. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B. Shapiro AD, Ragni MV, Lusher JM, Culbert S, Koerper MA, Bergman GE, Hannan MM. Thromb Haemost; 1996 Jan 01; 75(1):30-5. PubMed ID: 8713776 [Abstract] [Full Text] [Related] Page: [Next] [New Search]